Tigecycline
All Cause Mortality
-
All-cause mortality was higher in patients treated with tigecycline than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable.
FDA and Industry Communications
Patient Counseling Information
Package Inserts
Updated September 2018